Literature DB >> 8128172

Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors.

L Kay1, T Jørgensen.   

Abstract

The prevalence, incidence, natural history, and risk factors of upper dyspepsia (UD) were evaluated in a random sample of Danes. Of the 4581 eligible subjects, 79% responded. Five years later 85% of the survivors attended a similar follow-up study. Depending on the frequency of the symptoms, the prevalence of UD was 13-54% among men and 15-47% among women, and the incidence was 5-22% and 6-25%, respectively. Five years later 26-69% of subjects with UD were free from symptoms. As an independent factor psychic vulnerability was most strongly related to prevalence and incidence of UD, whereas experience of problems, smoking, and body mass index were only weakly associated with prevalence of UD. A comparison of the populations identified by various definitions of UD showed that these populations had rather few subjects in common. In conclusion, UD occurs frequently and fluctuates in the general population. Only psychic vulnerability was strongly related to UD incidence. The syndrome, however, still needs to be verified as a disease entity.

Entities:  

Mesh:

Year:  1994        PMID: 8128172

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  28 in total

1.  Obesity and gastrointestinal sensory-motor function.

Authors:  G Anton Decker; Michael D Crowell
Journal:  Curr Treat Options Gastroenterol       Date:  2005-08

Review 2.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

3.  Relation between Helicobacter pylori infection and gastrointestinal symptoms and syndromes.

Authors:  S Rosenstock; L Kay; C Rosenstock; L P Andersen; O Bonnevie; T Jørgensen
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

4.  An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.

Authors:  S J Veldhuyzen van Zanten; N Flook; N Chiba; D Armstrong; A Barkun; M Bradette; A Thomson; F Bursey; P Blackshaw; D Frail; P Sinclair
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

5.  Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15 000 Australian adults.

Authors:  P Bytzer; S Howell; M Leemon; L J Young; M P Jones; N J Talley
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

6.  Dyspepsia and health care seeking in a community: How important are psychological factors?

Authors:  N J Talley; P Boyce; M Jones
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

7.  Uninvestigated dyspepsia in Latin America: a population-based study.

Authors:  Jorge A Olmos; Valeria Pogorelsky; Federico Tobal; Mariano Marcolongo; Graciela Salis; Roberto Higa; Juan Carlos Chiocca
Journal:  Dig Dis Sci       Date:  2006-10-06       Impact factor: 3.199

8.  Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan.

Authors:  Toshikatsu Okumura; Sachie Tanno; Masumi Ohhira; Satoshi Tanno
Journal:  J Gastroenterol       Date:  2009-12-08       Impact factor: 7.527

9.  Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.

Authors:  R H Hunt
Journal:  CMAJ       Date:  1996-01-01       Impact factor: 8.262

10.  Irritable bowel syndrome and upper dyspepsia among the elderly: a study of symptom clusters in a random 70 year old population.

Authors:  L Kay; T Jørgensen; K Schultz-Larsen; M Davidsen
Journal:  Eur J Epidemiol       Date:  1996-04       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.